Results 101 to 110 of about 33,742 (116)

Compassionate Use of Remdesivir for Patients with Severe Covid-19

New England Journal of Medicine, 2020
Erika Asperges, Antonella Castagna, Emanuele Nicastri   +2 more
exaly  

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Lancet, The, 2020
Guan-Hua Du, Jianping Zhao, Yang Jin
exaly  

Remdesivir for the Treatment of Covid-19 — Final Report

New England Journal of Medicine, 2020
John H Beigel, Lori E Dodd, Aneesh K Mehta   +2 more
exaly  

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

New England Journal of Medicine, 2020
Jason D Goldman, David Lye, Raffaele Bruno   +2 more
exaly  

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial

Lancet Respiratory Medicine,the, 2021
Andre C Kalil, Mamta K Jain, Patrick E H Jackson   +2 more
exaly  

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Nature, 2020
Brandi N Williamson, Friederike Feldmann, Benjamin Schwarz   +2 more
exaly  

Remdesivir and COVID-19

Lancet, The, 2020
Jessie K Edwards, Stephen R Cole, Adaora A Adimora   +2 more
exaly   +2 more sources

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Clinical Infectious Diseases, 2021
Katherine K Perez, Alan S Go, Eboni G Price-Haywood   +2 more
exaly  

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

Cell Reports, 2020
Andrea J Pruijssers, Amelia S George, Sarah R Leist   +2 more
exaly  

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

Lancet, The, 2022
exaly